Key change in the dome of Novo Nordisk, one of the large world pharmaceutical groups, which has become one of the main companies in the segment of treatments against obesity and diabetes, such as the popular Ozempic and Wegovy. The company has communicated this Friday that its CEO, Lars Fruergaard Jorgensen, has presented the resignation. An exit that comes after the strong punishment suffered by the actions, especially since mid -2024. A statement. Jorgensen will continue as CEO to the election of the substitute, to facilitate the transition period. The manager joined Novo Nordisk in 1991 and amounted to the position of CEO in January 2017. The firm has indicated that in the last eight years it has tripled its sales and its benefits, thanks to its strong portfolio of products and the leadership of the management team. The company, however, has indicated that the substitute will be announced soon. In relation to the changes, Lars Rebien Sørensen, president of the Novo Nordisk Foundation, will join the Board of Directors, initially as an observer. However, the company’s intention is for the manager to join as a counselor at the Board of Shareholders of 2026. After having been one of the great European stars, becoming the first company of the old continent for stock market capitalization, in hard competition with LVMH and SAP, Novo Nordisk has suffered a hard punishment in recent times. The company, which competes with firms such as Eli Lilly, has seen how its actions fell more than a third since the beginning of January and more than 50% of its value during the last year. After the announcement of the future change in the directive dome, the actions of the pharmacist has deepened in the falls, becoming more than 3% last noon. Near the closure, however, the falls were stopped to the 1.5%. Millions of Danish crowns (about 3,890 million euros), a figure that represents a 14% growth in relation to the same period of the previous year. Sales amounted to 10,464 million euros, 19% more, thanks to the treatments against obesity, which raised their sales 67%. (Tagstotranslate) Companies (T) Pharmaceutical Industry (T) Novo Nordisk (T) Eli Lilly (T) Diabetes (T) Diabetes
